What TM 200 Treats: Main Uses and Benefits

TM 200 (Oxytetracycline) is a tetracycline-class antibiotic applied across domains where additional symptomatic support is needed to address bacterial infections. The active ingredient is utilized as an antibacterial agent against a variety of susceptible microorganisms.

The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns, and may be part of symptomatic management for systemic diseases like Rickettsial infections (typhus), specific atypical pneumonia syndromes, and conditions presenting with inflammatory manifestations, such as moderately severe acne vulgaris and certain bacterial eye infections. It is also applicable in treating select acute conditions, including urinary tract infections (UTIs), Chlamydia infections, and acute flare-ups of chronic bronchitis.

It may assist with symptom clusters that interfere with daily comfort, contributing to improved comfort during periods of heightened symptoms. It is considered relevant as a therapeutic alternative for patients with penicillin allergies.

Quick Fact: Relief for Systemic and Localized Symptoms	Domain	Symptom Clusters
Systemic	Symptoms related to systemic imbalance (fever, chills, fatigue)
Localized	Symptoms related to inflammatory or irritative states (lesions, discharge)

Who Can and Cannot Use TM 200?

Eligibility to use TM 200 (Oxytetracycline) is strictly defined by regulatory documentation, focusing on patient safety across developmental stages and coexisting health conditions.

Contraindicated Populations The medicine is absolutely contraindicated for patients with a known hypersensitivity to Oxytetracycline or any other drug in the tetracycline class. It must not be used by individuals diagnosed with porphyria or Systemic Lupus Erythematosus (SLE).

Age and Developmental Restrictions TM 200 is prohibited in routine treatment for children under the age of 8 years and is contraindicated during the last half of pregnancy. This restriction is due to the documented risk of permanent dental discoloration and inhibition of bone growth. The medicine is otherwise generally approved for use in adults and children above 8 years of age.

Condition-Based Eligibility Use is not recommended for women who are breastfeeding. Patients with impaired renal function or hepatic impairment are eligible only under restricted, conditional use, which often necessitates close monitoring and careful dose modification to avoid drug accumulation.

Interaction Scope

Medicinal product categories with documented interactions include Divalent/Trivalent Cation Salts (e.g., Antacids, Iron supplements), Oral Retinoids, Enzyme Inducers (e.g., Phenytoin), Anticoagulants, Penicillins, and the anesthetic Methoxyflurane. The mechanistic basis of these interactions, as stated in regulatory sources, is officially classified as Pharmacokinetic (Chelation, Enzyme Induction) and Pharmacodynamic (Potentiation, Antagonism). A timing-based restriction is mandated for cation-containing medicines, which must be administered 2 to 3 hours apart from TM 200. The formal restriction is that combinations with Methoxyflurane and Oral/Systemic Retinoids are officially contraindicated.

---

Interaction Classifications (High-Level)

Interaction severity is classified in official documents as Contraindicated (Absolute Prohibition), Clinically Significant (requiring co-medication monitoring), and Absorption-reducing (necessitating mandatory separation). The regulatory basis defines that the reduced absorption interaction requires constraints related to timing and substance content (cation presence), while other interactions require recognizing the potential for potentiated or antagonistic effects on co-administered medicines.

---

Official Interaction Statements

• Contraindicated Combinations: Co-administration with Methoxyflurane is prohibited due to the risk of fatal renal toxicity, and the combination with Oral/Systemic Retinoids is prohibited due to the documented risk of benign intracranial hypertension.
• Reduced Absorption: The oral absorption of TM 200 is substantially reduced by products containing divalent or trivalent cations (e.g., antacids, iron supplements), leading to the mandated timing separation. Reduced exposure is also documented with dairy products and alcohol.
• Pharmacodynamic Effects: TM 200 may potentiate the effect of oral anticoagulants and may antagonize the bactericidal activity of Penicillins.

Blocking the Bacterial Protein Factory (Ribosomal Inhibition)

The active ingredient, Oxytetracycline hydrochloride, functions as an inhibitor by selectively targeting the bacterial 30S ribosomal subunit, which is the cellular machinery responsible for creating proteins. The drug binds reversibly to the A-site (Acceptor site) on the ribosome. This molecular binding physically blocks the essential attachment of aminoacyl-tRNA molecules, thereby inhibiting the entire bacterial protein synthesis pathway.

Arresting Growth to Modulate Pathogen Population

The functional consequence of blocking protein synthesis is bacteriostasis—the total arrest of the bacterial cell's ability to grow, divide, and multiply. This physiological change prevents the pathogen population from increasing, limiting the microbial load and allowing the host's immune defenses to interact with the non-replicating bacterial cells.

Limitations Due to Bacterial Counter-Mechanisms

The drug's mechanism is mechanistically constrained by acquired antibiotic resistance. Resistance factors, such as bacterial efflux pumps or ribosomal protection proteins, actively override the intended drug action by either expelling Oxytetracycline from the cell or preventing its binding to the 30S ribosome, which compromises the intended inhibition of bacterial cell proliferation.

How to use Terramycin 200® for Fish

Terramycin 200® (oxytetracycline dehydrate) is an aquaculture premix designed for use as a medicated feed to control certain bacterial diseases in fish and abalone, as well as for skeletal marking in finfish. Its use is governed by a Veterinary Feed Directive (VFD) and must be administered according to specific instructions to ensure efficacy and compliance with withdrawal periods.

---

Dosage and Administration

The product is incorporated into fish feed, which is then administered daily for a specified duration. The exact dosage and duration vary based on the fish species, the condition being treated, and the treatment regimen selected by the investigator. These regimens typically fall into two categories for finfish, and one for abalone.

Treatment Regimen	Target Dose (Oxytetracycline per 100 lbs fish/day)	Treatment Duration
Standard Therapeutic Finfish	2.5 –3.75 g	10 days
High Therapeutic Finfish	10 g	14 days
Standard Abalone	Up to 6.0 g	14 days

---

Important Considerations

• Veterinary Oversight: Use of Terramycin 200® requires a valid VFD from a licensed veterinarian, who will determine the appropriate dose and withdrawal period for the specific scenario.
• Medicated Feed: The product is not administered directly but must be uniformly mixed into an appropriate feed formulation.
• Withdrawal Period: A mandatory withdrawal period must be observed between the last day of treatment and the legal harvest or slaughter for market to ensure the absence of drug residues in the product. This period is critical and varies significantly (e.g., 21 days to 70 days) based on the dosage and regimen used.
• Drug Discharge: Any discharge of the drug must comply with local regulatory requirements, such as NPDES permitting, to protect aquatic environments.

Research Evidence / Overview of Studies for TM 200

---

Evidence for Use in Moderately Severe Acne Vulgaris

TM 200 (Oxytetracycline) was studied for its use in managing the bacterial component of moderately severe acne vulgaris. Short-term and intermediate-term randomized controlled trials (RCTs) represent the highest level of research available for this indication, primarily examining outcomes related to changes in inflamed lesion counts and overall acne severity in adolescents and adults. Studies reported measurements of reductions in inflammatory lesion counts compared to baseline. Research provides insight into short-term changes over defined time intervals, though long-term durability of the response beyond study follow-up periods remains uncertain. Research is ongoing to assess the influence of antibiotic resistance on its effectiveness.

---

Evidence for Use in Acute Systemic Infections

The research structure for TM 200's use in acute systemic infections, such as Rickettsial infections (e.g., typhus) and atypical pneumonia syndromes, is based on diverse study types. For Rickettsial diseases, the evidence largely stems from historical comparative clinical trials and observational case series, which is the basis for its listing in certain reference medical resources. These studies examined outcomes related to systemic imbalance, such as changes monitored in fever and other acute symptoms. However, there is a lack of large-scale, contemporary randomized controlled trials directly comparing TM 200 to contemporary standard-of-care antibiotic therapies.

---

Evidence in Different Patient Groups and Contexts

Controlled trials, particularly those for acne, primarily involved generally healthy adolescents and adults. The evidence also includes its evaluation in study groups defined by allergies to other antibiotics, such as penicillin, which describes its evaluation in specific patient groups who had documented reasons for not using certain alternative antibiotic classes. However, data for certain groups remain insufficient. For instance, most major trials were conducted on non-pregnant adult populations, and there is limited information specifically focused on older adults or very young children. Consequently, the results apply only to the populations studied and cannot be assumed to reflect outcomes for all age or comorbidity groups.

Key Studies & References Oxytetracycline (Monograph and Use Profile)

Common questions about TM 200 (FAQ)

---

Q: What is TM 200 used for?

TM 200 is an approved medicine that is used to treat a specific type of bacterial infection in adults and children who meet the official eligibility criteria. According to the regulatory documents, its active component works by inhibiting the growth of certain susceptible bacteria.

---

Q: Can I take TM 200 if I am pregnant or breastfeeding?

Official product information states that TM 200 should only be used during pregnancy or breastfeeding if a medical professional determines that the potential benefit justifies the potential risk to the fetus or child. This determination is based on the limited data available and is an essential discussion to have with a healthcare provider before initiating therapy.

---

Q: What should I do if I miss a dose of TM 200?

Regulatory guidance suggests that if a dose is missed, it can be taken as soon as it is remembered unless it is nearly time for the next scheduled dose. Official documents advise against taking a double dose to make up for a missed one. Afterward, the prescribed dosing schedule is typically continued as usual.

---

Q: Does TM 200 cause drowsiness or affect my ability to drive?

Studies and official information indicate that TM 200 can, in some cases, cause side effects such as dizziness or tiredness, which may affect concentration and the ability to react. Due to the potential for these effects, patients may need to exercise caution when engaging in activities such as driving or operating heavy machinery until they understand their individual response to the medication.

---

Q: How long does it take for TM 200 to start working?

The time it takes for TM 200 to start showing clinical effect can vary depending on the patient and the severity of the infection. Official product information indicates that an improvement in symptoms is typically observed within a few days of starting the prescribed course of therapy. Regulatory documents emphasize the importance of completing the full course of therapy as prescribed.

---

Q: Is TM 200 an antibiotic?

Yes, TM 200 is classified as an antibiotic. Its mechanism of action involves targeting and inhibiting a specific process necessary for the survival of susceptible bacteria, which helps to clear the bacterial infection it is approved to treat.

Official Storage and Disposal Requirements for TM 200

The medicine TM 200 (Oxytetracycline hydrochloride) must be stored under specific environmental conditions as defined by regulatory documents to maintain its stability and efficacy.

Storage Component	Official Requirement
Temperature	Store at controlled room temperature between 20°C and 25°C (68°F and 77°F). Brief excursions up to 30°C are permitted.
Protection	Must be protected from light and excessive heat; keep the container tightly closed to prevent moisture exposure.
Container Rule	Keep the product in the original container it was dispensed in. Certain liquid forms are labeled with a 'Do not freeze' instruction.
Safety	Store this product out of the sight and reach of children.

Unused or expired TM 200 must be managed according to official waste guidelines. The product must be disposed of through an official drug take-back program and should not be flushed down the toilet or poured into household wastewater.